Autoimmune Hemolytic Anemia

Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made based on individual patient circumstances, clinician judgment, and the most current evidence and guidelines.

Overview

• Definition: Autoimmune hemolytic anemia (AIHA) is a group of acquired disorders characterized by the premature destruction of red blood cells (RBCs) by autoantibodies directed against intrinsic RBC antigens. This leads to a reduction in RBC mass and anemia.
• Epidemiology:
  • Incidence: Approximately 1-3 cases per 100,000 people per year.
  • Prevalence: Around 17 cases per 100,000 people.
  • Age: Can occur at any age. Warm AIHA (WAIHA) has a bimodal distribution, peaking in childhood (often acute and self-limiting) and again in middle to older age. Cold agglutinin disease (CAD) typically affects individuals over 50 years. Paroxysmal Cold Hemoglobinuria (PCH) is rare and most common in children, often following viral infections.
  • Sex: WAIHA is more common in females (female-to-male ratio ~2:1), while CAD shows a slight female predominance or no significant difference.
• Classification: AIHA is broadly classified based on the thermal amplitude and immunoglobulin class of the autoantibodies involved:
  • Warm Autoimmune Hemolytic Anemia (WAIHA):
    • Caused by IgG autoantibodies that react optimally at body temperature (37°C).
    • Accounts for ~70-80% of AIHA cases.
    • Hemolysis is primarily extravascular, occurring in the spleen and liver.
    • Can be primary (idiopathic) or secondary to underlying conditions (e.g., systemic lupus erythematosus (SLE), chronic lymphocytic leukemia (CLL), lymphomas, other autoimmune diseases, certain medications).
  • Cold Agglutinin Disease (CAD):
    • Caused by IgM autoantibodies that react optimally at lower temperatures (<37°C), typically 0-4°C.
    • Accounts for ~15-20% of AIHA cases.
    • Hemolysis is predominantly intravascular (due to complement activation) and extravascular (via C3b-mediated opsonization).
    • Can be primary (idiopathic) or secondary (e.g., Mycoplasma pneumoniae infection, Epstein-Barr virus (EBV), lymphoproliferative disorders like Waldenström macroglobulinemia, CLL, lymphomas).
  • Mixed-Type AIHA:
    • Presence of both warm-reactive IgG autoantibodies and cold-reactive IgM autoantibodies.
    • Accounts for ~5-10% of cases.
    • Often more severe due to combined mechanisms of hemolysis.
  • Paroxysmal Cold Hemoglobinuria (PCH):
    • Rare, severe form of cold AIHA caused by a biphasic IgG autoantibody (Donath-Landsteiner antibody) that binds to RBCs in the cold and causes complement-mediated lysis upon warming.
    • Accounts for <5% of AIHA cases.
    • Often secondary to viral infections (e.g., measles, mumps, EBV, CMV) in children or syphilis in adults.
  • Drug-Induced AIHA:
    • Certain drugs can induce AIHA via various mechanisms (e.g., drug-dependent antibodies, drug adsorption, immune complex formation, autoantibody induction). Common culprits include cephalosporins, penicillin, methyldopa, fludarabine.

Pathophysiology

• Mechanism:
  • Warm AIHA (WAIHA):
    • IgG autoantibodies bind to RBC surface antigens (e.g., Rh proteins).
    • Fc portion of IgG-coated RBCs is recognized by Fc receptors on macrophages in the spleen and liver (extravascular hemolysis).
    • Partial phagocytosis (resulting in spherocytes) or complete phagocytosis leads to RBC destruction.
    • Complement activation may occur, leading to C3b opsonization, further enhancing phagocytosis. Intravascular hemolysis is less common but can occur if complement cascade goes to completion.
  • Cold Agglutinin Disease (CAD):
    • IgM autoantibodies bind to I/i antigens on RBCs at cooler temperatures, typically in peripheral circulation (extremities).
    • Binding of IgM efficiently activates the classical complement pathway, leading to C3b deposition on RBCs.
    • As RBCs return to warmer temperatures, IgM dissociates, but C3b remains.
    • C3b-coated RBCs are then cleared by macrophages in the liver (which have more C3b receptors than splenic macrophages) or spleen, leading to extravascular hemolysis.
    • If complement activation goes to completion, it can form the membrane attack complex (MAC), leading to direct intravascular lysis of RBCs.
  • Paroxysmal Cold Hemoglobinuria (PCH):
    • The biphasic Donath-Landsteiner antibody (IgG, usually specific for P antigen) binds to RBCs in cooler temperatures (e.g., extremities).
    • Upon warming (e.g., returning to core body temperature), the bound antibody fixes complement, leading to massive intravascular hemolysis via MAC formation.
• Risk Factors:
  • Genetic Predisposition: Certain HLA genotypes may confer susceptibility.
  • Autoimmune Disorders: SLE, rheumatoid arthritis, Sjogren's syndrome, inflammatory bowel disease, autoimmune thyroid disease.
  • Lymphoproliferative Disorders: Chronic lymphocytic leukemia (CLL) is the most common association, non-Hodgkin lymphomas, Hodgkin lymphoma, Waldenström macroglobulinemia (especially with CAD).
  • Infections:
    • Viral: EBV, CMV, HIV, hepatitis C, measles, mumps (especially for PCH).
    • Bacterial: Mycoplasma pneumoniae (common cause of secondary CAD, especially in children), syphilis (PCH).
  • Immunodeficiency States: Common variable immunodeficiency (CVID), IgA deficiency.
  • Solid Tumors: Renal cell carcinoma, ovarian cancer (less common).
  • Medications: Alpha-methyldopa, penicillin, cephalosporins, fludarabine, cladribine, NSAIDs, quinine, etc.
  • Bone Marrow Transplant: Both autologous and allogeneic.
• Protective Factors: No known specific protective factors against the development of AIHA itself. Early diagnosis and management of underlying conditions may help mitigate severity or prevent recurrence.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Anemia: Fatigue, weakness, pallor, dyspnea on exertion, dizziness, headache, palpitations. Severity of symptoms depends on rate of onset and degree of anemia.
  • Jaundice/Icterus: Due to increased indirect bilirubin from hemolysis.
  • Dark Urine (Hemoglobinuria/Bilirubinuria): Hemoglobinuria (red to brown urine) indicates significant intravascular hemolysis (common in CAD, PCH, severe WAIHA). Bilirubinuria (dark urine) suggests conjugated hyperbilirubinemia, which can occur in severe cases if the liver's conjugating capacity is overwhelmed or liver damage occurs.
  • Splenomegaly: Common in WAIHA (due to extravascular hemolysis in the spleen), typically mild to moderate. Less common or absent in CAD or PCH.
  • Hepatomegaly: Can occur in severe cases, especially with high rates of extravascular hemolysis.
  • Symptoms of underlying disease: Arthralgia, rash (SLE), lymphadenopathy (lymphoproliferative disorders), cold-induced acrocyanosis/Raynaud's phenomenon (CAD).
• Early Signs: Mild fatigue, subtle pallor, mild jaundice. Symptoms may be insidious or acute.
• Advanced Signs: Severe pallor, signs of heart failure (tachycardia, edema, dyspnea at rest), shock, syncope, acute kidney injury (from severe intravascular hemolysis leading to hemoglobinuria and tubular necrosis), severe jaundice.
• Atypical Presentations:
  • Hemolysis without significant anemia (compensated hemolysis, especially early on).
  • Fluctuating severity of symptoms.
  • Predominant symptoms of underlying disease masking AIHA.
  • Evan's Syndrome: AIHA co-occurring with immune thrombocytopenia (ITP) and sometimes immune neutropenia.

Physical Examination

• Inspection:
  • Pallor: Of conjunctivae, mucous membranes, nail beds.
  • Jaundice/Icterus: Yellow discoloration of skin and sclera.
  • Petechiae/Purpura: If associated with thrombocytopenia (Evan's Syndrome).
  • Acrocyanosis/Raynaud's phenomenon: Blue discoloration of fingers/toes/nose/ears, aggravated by cold exposure (characteristic of CAD).
  • Dark urine: If visible, indicates hemoglobinuria or severe bilirubinuria.
• Palpation:
  • Splenomegaly: Palpable spleen often indicates WAIHA. Assess size below costal margin.
  • Hepatomegaly: Less common, may indicate severe hemolysis or underlying liver disease.
  • Lymphadenopathy: May suggest underlying lymphoproliferative disorder.
• Special Tests: Not specific physical exam tests for AIHA beyond general systemic assessment. Assess for signs of heart failure, fluid overload, or neurological compromise if severe.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and Progression: Acute vs. insidious onset of symptoms. Rapid worsening?
  • Symptoms of Anemia: Fatigue, dyspnea, dizziness, syncope.
  • Symptoms of Hemolysis: Jaundice, dark urine (color, timing), abdominal pain.
  • Cold Exposure Symptoms: Raynaud's phenomenon, acrocyanosis, pain in extremities, or worsening of symptoms after cold exposure (suggests CAD/PCH).
  • Medication History: All current and recent medications, including over-the-counter drugs, herbal supplements. Specific inquiry about drugs known to cause AIHA (e.g., cephalosporins, penicillin, methyldopa, fludarabine).
  • Past Medical History: History of autoimmune diseases (SLE, RA, IBD), chronic infections (HIV, hepatitis, Mycoplasma), malignancy, recent transfusions, bone marrow transplant.
  • Family History: Any family history of autoimmune diseases or hemolytic anemias.
  • Travel History/Infections: Recent travel, exposure to infections.
• Red Flags:
  • Rapidly worsening anemia with signs of hypovolemic shock.
  • Severe hemoglobinuria with signs of acute kidney injury.
  • Severe dyspnea at rest, chest pain, or other signs of heart failure.
  • Neurological symptoms (e.g., altered mental status) that might suggest thrombotic microangiopathy (TMA) as a differential or complication.

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC) with Differential:
    • Hemoglobin/Hematocrit: Reduced, indicating anemia.
    • Mean Corpuscular Volume (MCV): Often normal or slightly elevated due to reticulocytosis.
    • Red Cell Distribution Width (RDW): Often elevated.
    • Platelet Count: Usually normal, but can be low in Evan's Syndrome.
    • White Blood Cell Count (WBC): May be normal, elevated (due to infection/inflammation), or low (e.g., in SLE, lymphoproliferative disorders).
  • Reticulocyte Count: Elevated (absolute count >100,000/µL or corrected reticulocyte count >2-3%) in compensated or ongoing hemolysis, indicating bone marrow response. May be inappropriately low if marrow is suppressed (e.g., parvovirus B19 infection, underlying marrow disease).
  • Peripheral Blood Smear:
    • Spherocytes: Characteristic of extravascular hemolysis (WAIHA). Small, dense RBCs lacking central pallor.
    • Polychromasia: Blue-tinged RBCs, indicating reticulocytes.
    • Rouleaux formation/RBC Agglutination: Clumping of RBCs on smear (suggests cold agglutinins).
    • Nucleated Red Blood Cells (NRBCs): May be present in severe hemolysis.
    • Schistocytes: Suggests microangiopathic hemolytic anemia (TMA) as a differential, but generally not characteristic of AIHA.
  • Indirect Markers of Hemolysis:
    • Lactate Dehydrogenase (LDH): Elevated due to RBC destruction.
    • Indirect Bilirubin: Elevated due to increased heme breakdown.
    • Haptoglobin: Decreased or undetectable due to binding of free hemoglobin; highly sensitive but not specific (can be falsely normal/elevated in inflammatory states).
  • Direct Antiglobulin Test (DAT or Coombs Test): Cornerstone of AIHA diagnosis.
    • Detects antibodies and/or complement components fixed to the surface of RBCs.
    • Positive DAT: Confirms immune-mediated hemolysis.
      • WAIHA: Typically IgG, often with C3d. Some cases are IgG-only, C3d-only, or IgA.
      • CAD: Typically C3d-only or C3d with IgM. Rarely IgG.
      • PCH: Typically C3d-only or IgG.
    • Negative DAT: While rare (<5-10% of cases), can occur in AIHA (e.g., very low antibody affinity/quantity, IgA-AIHA (if not specifically tested), or certain drug-induced AIHA). If suspicion remains high, consider further workup.
• Confirmatory:
  • DAT Panel with Monospecific Reagents: To identify the specific immunoglobulin class (IgG, IgM, IgA) and complement components (C3d) coating RBCs. Essential for classification and guiding therapy.
  • Eluate Studies: If the DAT is positive, an eluate (antibody removed from patient RBCs) can be tested against a panel of reagent RBCs to determine the specificity of the autoantibody (e.g., anti-Rh, anti-I/i). This is especially useful for differentiating autoantibodies from alloantibodies (e.g., in a recently transfused patient).
  • Cold Agglutinin Titer: Performed if CAD is suspected (positive C3d on DAT, RBC agglutination on smear). Titers >1:64 at 4°C are clinically significant; titers >1:512 often correlate with symptomatic CAD.
  • Thermal Amplitude: For cold agglutinins, measures the highest temperature at which the antibody reacts with RBCs. Higher thermal amplitude correlates with more severe disease.
  • Donath-Landsteiner Test: Confirmatory for PCH. Demonstrates biphasic hemolysis (sensitization at cold temperatures, lysis upon warming).
  • Rule Out Secondary Causes:
    • Autoimmune serologies: ANA, anti-dsDNA, anti-Sm, anti-Ro/La (for SLE).
    • Infection serologies: Mycoplasma IgM, EBV, CMV, HIV, hepatitis C.
    • Lymphoproliferative workup: Flow cytometry of peripheral blood (for CLL), protein electrophoresis (for Waldenström), CT scans (for lymphoma), bone marrow biopsy if indicated.
    • Drug history review: Careful review and consider drug discontinuation.
• Monitoring:
  • CBC with Reticulocyte Count: Daily or every few days during acute phase, then weekly/monthly during chronic management to assess response and detect relapse.
  • LDH, Indirect Bilirubin, Haptoglobin: To monitor hemolytic activity.
  • DAT: Not typically used for routine monitoring of disease activity or treatment response, as it may remain positive even in remission.

Imaging

• Recommended:
  • Abdominal Ultrasound: To assess spleen size (splenomegaly supports WAIHA), evaluate for gallstones (common in chronic hemolytic states due to bilirubin).
  • CT Chest/Abdomen/Pelvis: If secondary AIHA is suspected, especially to screen for underlying lymphoproliferative disorders (lymphadenopathy, splenomegaly, hepatomegaly) or other malignancies.
• Advanced:
  • PET-CT Scan: May be considered in cases of unexplained secondary AIHA where conventional imaging is negative but suspicion of occult malignancy (especially lymphoma) remains high.

Management

Acute Management

• Immediate:
  • Secure Airway, Breathing, Circulation (ABCs): Assess patient stability.
  • Blood Transfusion: Indicated for severe, symptomatic anemia (Hb <7 g/dL or lower if asymptomatic and stable, or higher if symptomatic/cardiac compromise).
    • Cross-matching: Can be challenging due to panagglutination from autoantibodies. Type-specific cross-matched blood is preferred. If cross-match is incompatible, transfuse ABO/Rh-matched O-negative or type-specific packed RBCs as an emergency.
    • WAIHA: Transfused blood is also susceptible to autoantibody destruction. Transfusion should be slow and monitored for adverse reactions.
    • CAD: Use a blood warmer to prevent agglutination of donor cells.
  • Intravenous Immunoglobulin (IVIG): Consider high-dose IVIG (0.4-1 g/kg/day for 2-5 days, or 1 g/kg/day for 2 days) in severe, rapidly progressive AIHA or if response to corticosteroids is inadequate/delayed. Mechanism involves blocking Fc receptors on macrophages, reducing antibody production, and modulating complement.
• Stabilization:
  • High-Dose Corticosteroids: First-line therapy for WAIHA.
    • Prednisone: 1-2 mg/kg/day orally (up to 60-100 mg/day) or equivalent intravenous methylprednisolone for severe cases (e.g., 1 mg/kg IV every 6 hours).
    • Initiate immediately upon diagnosis of WAIHA. Response usually seen within 3-7 days.
    • Once Hb stabilizes and reticulocyte count rises, gradually taper the dose over weeks to months to the lowest effective dose.
  • Folic Acid Supplementation: 1 mg/day orally, to support increased erythropoiesis.
  • Fluid Management: Maintain adequate hydration to prevent renal complications from hemoglobinuria.
• Emergency:
  • Management of Hyperkalemia: From massive intravascular hemolysis. Treat with insulin/glucose, calcium gluconate, diuretics, etc.
  • Management of Acute Kidney Injury: From hemoglobinuria. Maintain urine output, consider dialysis in severe cases.
  • Management of Heart Failure: From severe anemia. Transfusion, oxygen, diuretics.

Chronic Management

Pharmacological

• Warm AIHA (WAIHA):
  • First-line: Corticosteroids (prednisone/prednisolone). Taper slowly once response is achieved.
  • Second-line (for refractory/relapsing disease or steroid-sparing):
    • Rituximab: Anti-CD20 monoclonal antibody. Often preferred second-line agent.
      • Dose: 375 mg/m² IV weekly for 4 doses (standard lymphoma regimen) or 1000 mg IV on days 1 and 15 (rheumatology regimen). Response rates ~70-80%.
      • Effective in steroid-refractory or steroid-dependent WAIHA.
    • Splenectomy: Considered for steroid-refractory or steroid-dependent WAIHA.
      • Historically a common second-line, but declining with rituximab use.
      • Removes primary site of RBC destruction and antibody production.
      • Response rates ~60-80%.
      • Requires pre-operative vaccination against encapsulated bacteria (Pneumococcus, Meningococcus, H. influenzae).
    • Other Immunosuppressants:
      • Mycophenolate Mofetil (MMF): 1-1.5 g orally twice daily. Slower onset of action.
      • Azathioprine: 1-2 mg/kg/day orally. Slower onset.
      • Cyclosporine A: 3-5 mg/kg/day orally in divided doses. Requires therapeutic drug monitoring.
      • Danazol: Androgenic steroid (200-800 mg/day orally). Can be effective as a steroid-sparing agent with fewer side effects than other immunosuppressants.
  • Novel Agents (for chronic WAIHA):
    • Fostamatinib: Oral spleen tyrosine kinase (SYK) inhibitor. Approved for chronic immune thrombocytopenia but shows promise in chronic WAIHA. Dose: 100 mg orally twice daily, can be increased to 150 mg twice daily.
• Cold Agglutinin Disease (CAD):
  • First-line:
    • Rituximab: Standard first-line therapy for symptomatic primary CAD. Similar dosing as for WAIHA. Response rates ~50-60%.
    • Corticosteroids and Splenectomy are generally ineffective in CAD.
  • Second-line (for refractory/relapsing CAD):
    • Rituximab combined with Bendamustine: Effective in some cases, particularly if associated with lymphoproliferative disorder.
    • Bortezomib: Proteasome inhibitor. Effective in patients with severe CAD, particularly those with underlying lymphoproliferative disorders.
    • Sutimlimab: C1s inhibitor. Blocks the classical complement pathway, preventing hemolysis. Approved for CAD. Dose: 6.5 mg/kg IV on Days 0 and 7, then every 2 weeks.
    • Other: Cyclophosphamide, fludarabine (caution due to increased risk of infections and secondary malignancies).
• Paroxysmal Cold Hemoglobinuria (PCH):
  • Avoid cold exposure: Primary management strategy.
  • Corticosteroids/IVIG: May be used for severe acute episodes, but less effective than in WAIHA.
  • Management of underlying infection (e.g., syphilis) is crucial.
• Drug-Induced AIHA:
  • Discontinue offending drug: Most effective treatment. Hemolysis typically resolves within weeks to months.
  • Corticosteroids may be used for severe cases, but often not necessary once the drug is stopped.

Non-pharmacological

• Avoidance of Triggers:
  • Cold Exposure: Essential for CAD and PCH patients (dress warmly, avoid cold drinks, cold environments).
  • Avoidance of Offending Drugs: For drug-induced AIHA.
• Supportive Care:
  • Folic Acid Supplementation: Continuous supplementation (1 mg/day) for ongoing hemolysis.
  • Nutritional Support: Ensure adequate nutrition.
  • Vaccinations: Pre-splenectomy vaccinations (Pneumococcal, Meningococcal, Hib) and annual influenza vaccination. Consider COVID-19 vaccination.
  • Infection Prophylaxis: Consider in patients on long-term immunosuppressants (e.g., PJP prophylaxis with trimethoprim-sulfamethoxazole).

Monitoring

• Long-term Follow-up:
  • Regular clinical evaluation for symptoms of anemia, hemolysis, and medication side effects.
  • Laboratory Monitoring:
    • CBC with Reticulocyte Count: Monthly or every 3-6 months in stable remission.
    • LDH, Indirect Bilirubin, Haptoglobin: Periodically to monitor hemolytic activity.
    • Monitoring for medication side effects: e.g., blood glucose and bone density for steroids, renal function for cyclosporine, CBC for myelosuppressive agents.
    • Screening for underlying conditions: Ongoing surveillance for development of lymphoproliferative disorders in primary AIHA, especially CAD.

Treatment Algorithms

• First-Line AIHA (WAIHA):
  1. High-dose Corticosteroids (Prednisone 1-2 mg/kg/day or IV equivalent).
  2. Transfusion support as needed. Folic acid supplementation.
• Second-Line AIHA (WAIHA) - for steroid-refractory or steroid-dependent cases:
  1. Rituximab (375 mg/m² weekly x 4 doses or 1000 mg x 2 doses).
  2. Consider Splenectomy if Rituximab fails or is contraindicated, after pre-operative vaccinations.
  3. Alternatively or in combination with Rituximab: Mycophenolate Mofetil, Azathioprine, Cyclosporine, or Danazol.

• Refractory AIHA (WAIHA):

  1. Consider Fostamatinib.
  2. Combination immunosuppressive regimens (e.g., Rituximab + MMF).
  3. High-dose cyclophosphamide.
  4. Hematopoietic stem cell transplant (rarely, for severe, life-threatening refractory cases).
  5. Clinical trials of novel agents.

• First-Line AIHA (CAD):

  1. Avoidance of cold exposure.
  2. Rituximab (375 mg/m² weekly x 4 doses or 1000 mg x 2 doses).
• Second-Line AIHA (CAD) - for refractory/relapsing CAD:
  1. Sutimlimab (C1s inhibitor).
  2. Combination of Rituximab + Bendamustine.
  3. Bortezomib.
  4. Consider chlorambucil or fludarabine if associated with lymphoproliferative disorder (with caution).

Complications

• Common:
  • Severe Anemia: Leading to fatigue, dyspnea, activity intolerance, and impaired quality of life.
  • Jaundice/Gallstones: Chronic hemolysis increases bilirubin production, predisposing to pigment gallstones.
  • Splenomegaly: Can cause abdominal discomfort or early satiety.
• Serious:
  • Acute Anemic Crisis: Potentially leading to circulatory collapse, acute kidney injury, or heart failure.
  • Transfusion Reactions: Challenges in cross-matching due to autoantibodies can lead to delayed hemolytic transfusion reactions.
  • Thromboembolism: Increased risk of venous thromboembolism (VTE) due to endothelial activation, inflammation, and hypercoagulability, especially during active hemolysis.
  • Infections: Increased risk due to immunosuppressive therapy (steroids, rituximab, other agents) and post-splenectomy sepsis (OPSI).
  • Acute Kidney Injury: From severe intravascular hemolysis (hemoglobinuria).
  • Pulmonary Hypertension: Rare, chronic complication of severe, longstanding anemia.
• Long-term:
  • Chronic Fatigue: Persistent despite treatment.
  • Steroid-related Side Effects: Osteoporosis, diabetes mellitus, hypertension, cataracts, glaucoma, weight gain, Cushingoid features, increased infection risk.
  • Recurrent Hemolysis: Relapse is common, requiring prolonged treatment.
  • Secondary Malignancies: Risk with certain immunosuppressants (e.g., purine analogs like fludarabine) or underlying lymphoproliferative disorders.

Prognosis

• Factors Affecting Outcome:
  • Type of AIHA: WAIHA generally has a better prognosis than severe CAD or PCH.
  • Primary vs. Secondary: Secondary AIHA prognosis largely depends on the underlying disease; if the underlying condition is treatable, AIHA may resolve.
  • Severity at Presentation: Patients with severe, rapidly progressive disease are at higher risk.
  • Response to Initial Therapy: Patients who respond well to corticosteroids generally have a better outlook.
  • Presence of Comorbidities: Significant comorbidities can complicate management and worsen outcomes.
• Survival:
  • Overall, the prognosis for primary WAIHA is relatively good, with mortality rates typically <10% in large series. Most deaths are related to complications (e.g., infection, thrombosis, heart failure) rather than directly from anemia.
  • Prognosis for CAD is more variable and often related to the underlying lymphoproliferative disorder, with higher morbidity/mortality.
  • PCH is rare but can be severe, especially in children; prognosis is good if the underlying trigger is identified and managed.
• Quality of Life: Can be significantly impacted by chronic fatigue, the need for long-term medication, frequent hospitalizations for transfusions, and medication side effects.

Prevention

• Primary: No specific primary prevention strategies for AIHA itself, as its etiology is often unknown or linked to genetic/unavoidable factors.
  • Early diagnosis and appropriate management of underlying autoimmune or lymphoproliferative disorders may help prevent the onset of secondary AIHA.
  • Avoidance of drugs known to cause AIHA if a patient has a history of drug-induced immune reactions.
• Secondary: Focus on early detection and intervention to minimize the severity of hemolytic episodes and prevent complications.
  • Prompt diagnosis of AIHA when symptoms arise.
  • Timely initiation of appropriate immunosuppressive therapy.
  • Regular monitoring for disease activity and response to treatment.
• Tertiary: Aimed at preventing recurrence, managing long-term complications, and improving quality of life.
  • Adherence to maintenance therapy and slow, careful tapering of corticosteroids.
  • Prophylactic vaccinations (especially post-splenectomy).
  • Monitoring for and managing medication side effects (e.g., osteoporosis screening and treatment, blood glucose monitoring).
  • Lifestyle modifications (e.g., avoiding cold in CAD/PCH).
  • Early identification and treatment of infections.

Special Populations

• Pediatric:
  • WAIHA is the most common form in children, often acute and self-limiting (especially if primary).
  • Secondary AIHA is also common, often associated with viral infections or immunodeficiency.
  • Corticosteroids are first-line. IVIG is often used early for severe cases due to its rapid action and good safety profile in children.
  • Splenectomy is generally reserved for refractory cases due to long-term risks (e.g., OPSI).
  • PCH is primarily a disease of children, often post-viral.
• Geriatric:
  • Higher incidence of secondary AIHA, particularly associated with CLL and other lymphoproliferative disorders.
  • More susceptible to severe anemia and complications (e.g., cardiac decompensation, renal failure).
  • Increased risk of medication side effects (e.g., steroid-induced diabetes/osteoporosis, immunosuppressant toxicities).
  • Comorbidities require careful consideration when selecting treatment. Lower doses or slower tapers of medications may be necessary.
• Pregnancy:
  • AIHA during pregnancy is rare but can be serious for both mother and fetus.
  • WAIHA is more common in pregnancy. Steroids are generally safe in pregnancy (prednisone, prednisolone do not cross placenta significantly). IVIG is also safe.
  • Rituximab use is controversial but may be considered in refractory cases during the second or third trimester (associated with neonatal B-cell depletion, usually transient).
  • Monitoring of fetal anemia (non-immune hydrops, middle cerebral artery Doppler) is crucial, as maternal autoantibodies rarely but can cross the placenta and cause neonatal AIHA. However, this is less common than alloimmune hemolytic disease.
  • CAD is rare in pregnancy, and cold exposure must be strictly avoided.
• Comorbidities:
  • Renal/Hepatic Dysfunction: Adjust medication dosages (e.g., MMF, cyclosporine, azathioprine). Increased risk of complications.
  • Cardiovascular Disease: Manage anemia aggressively to prevent cardiac decompensation. Carefully monitor fluid status during transfusion.
  • Immunodeficiency: Increased risk of severe infections with immunosuppressive therapy; may require prophylactic antibiotics or antifungals. Avoid further immunosuppressants if possible, or use with extreme caution.
  • Active Infection: Delay initiation or reduce intensity of immunosuppressive therapy until infection is controlled.

Clinical Pearls

• Diagnostic:
  • Always order a DAT (Direct Antiglobulin Test) if AIHA is suspected. It is the cornerstone of diagnosis.
  • A positive DAT does not always mean hemolysis: It can be positive in healthy individuals or certain drug exposures without clinical hemolysis. Always correlate with clinical signs of hemolysis (anemia, reticulocytosis, elevated LDH/indirect bilirubin, low haptoglobin).
  • Consider secondary causes: A positive DAT requires thorough investigation for underlying autoimmune diseases, lymphoproliferative disorders, or drug etiology. This is crucial for guiding definitive management.
  • Peripheral blood smear is invaluable: Look for spherocytes (WAIHA), agglutination (CAD), and evaluate for other causes of hemolysis (e.g., schistocytes in TMA).
  • Don't rely solely on haptoglobin: It's an acute phase reactant; elevated levels due to inflammation can mask its decrease from hemolysis.
• Treatment:
  • Steroid taper is critical: Abrupt discontinuation or rapid tapering of corticosteroids is a common cause of relapse in WAIHA. Taper slowly over weeks to months based on clinical and laboratory response.
  • Splenectomy is not first-line: While effective for WAIHA, it carries surgical risks and lifelong risk of overwhelming post-splenectomy infection (OPSI). Rituximab is often preferred as a second-line agent.
  • Transfusion in AIHA is challenging: Always communicate with the blood bank about AIHA. Use warmed blood for CAD. Be mindful of potential for alloantibody development or delayed hemolytic transfusion reactions.
  • Cold avoidance is paramount for CAD/PCH: Emphasize education to patients about avoiding cold temperatures.
• Pitfalls:
  • Misdiagnosing other hemolytic anemias: Ensure all parameters for AIHA are met and rule out non-immune hemolysis (e.g., G6PD deficiency, microangiopathic hemolytic anemia, inherited spherocytosis).
  • Underestimating severity: AIHA can be rapidly progressive and life-threatening. Close monitoring and aggressive initial management are essential.
  • Missing an underlying malignancy: Especially in older patients with CAD or refractory WAIHA, diligent search for occult lymphoproliferative disorders is necessary.
  • Inadequate infection prophylaxis: In immunosuppressed or splenectomized patients, failure to provide appropriate prophylaxis can lead to severe, life-threatening infections.

Recent Updates

• Guidelines:
  • American Society of Hematology (ASH) 2017 Guidelines for the Management of Warm Autoimmune Hemolytic Anemia: Provides evidence-based recommendations for initial and subsequent therapies, including corticosteroids, rituximab, and splenectomy.
  • European Consensus Recommendations on the Diagnosis and Treatment of Cold Agglutinin Disease (CAD): Offers comprehensive guidance for CAD management.
• Evidence:
  • Fostamatinib (SYK inhibitor): Emerging as a potential oral treatment option for chronic WAIHA refractory to steroids and other agents, with promising phase 3 data (e.g., FOSTAIR trial).
  • Sutimlimab (C1s inhibitor): Approved for CAD, demonstrating significant reduction in complement activation and hemolysis in clinical trials (e.g., CARDINAL study), providing a targeted therapy for this difficult-to-treat disease.
  • Increased recognition of IgA-AIHA: While rare, it is now more recognized as a distinct entity, sometimes requiring specific diagnostic reagents (anti-IgA on DAT) and potentially different treatment approaches.
• Controversies:
  • Optimal timing and sequencing of second-line therapies in WAIHA: The choice between rituximab and splenectomy, or other immunosuppressants, is still debated and often individualized.
  • Role of combination therapy upfront: Whether combination immunosuppression (e.g., corticosteroids + rituximab) offers superior outcomes or just increased toxicity compared to sequential monotherapy.
  • Long-term maintenance therapy: The need for and duration of maintenance therapy (e.g., low-dose rituximab) to prevent relapse remains an area of ongoing research.

Key References

• Guidelines:
  • Barcellini W, et al. Guidelines for the management of warm autoimmune hemolytic anemia in adults. Blood. 2017;130(7):1028-1038. (ASH Guidelines)
  • Jäger U, et al. Diagnosis and treatment of cold agglutinin disease: a European consensus. Blood Rev. 2020;41:100645.
• Studies:
  • Packman CH. The clinical pictures of autoimmune hemolytic anemia. Transfusion Medicine and Hemostasis. 3rd ed. 2019. (Chapter on AIHA)
  • Röth A, et al. Sutimlimab in patients with cold agglutinin disease. N Engl J Med. 2021;384(14):1323-1334. (CARDINAL study on Sutimlimab)
  • Michel M. Treatment of autoimmune hemolytic anemia: New agents and novel approaches. Semin Hematol. 2016;53(4):S23-S27.
• Reviews:
  • Bassin J, et al. Autoimmune Hemolytic Anemia: A Clinical Review. Medicina (Kaunas). 2023;59(2):339.
  • Lechner K, Jäger U. How I treat autoimmune hemolytic anemia in adults. Blood. 2010;116(11):1831-1838.